Aclaris Therapeutics to Present at the 2018 American Hair Research Summit
May 11 2018 - 7:00AM
Paul Changelian, Ph.D., Vice President, Biology, Aclaris
Therapeutics, Inc. (NASDAQ:ACRS), will speak at the 2018 American
Hair Research Summit on “Preclinical to Clinical Translation of JAK
Kinase Inhibitors" on May 15. The meeting is organized by the
American Hair Research Society (AHRS) and will take place May 14-16
in Orlando, Florida.
Dr. Changelian will review the history of drug discovery
targeting Janus kinase (JAK) enzymes. JAK inhibitors initially were
conceived as drugs to reduce organ transplant rejection but
gradually were found to have utility in autoimmune diseases and
oncology. Harnessing the benefits of JAK inhibition for
dermatological conditions will require minimizing the potential for
over suppression of the immune system and subsequent infections,
through strategies such as identifying molecules highly selective
for JAK1 and JAK3 inhibition or developing topical formulations
with high skin permeability while minimizing systemic absorption.
Current efforts to expand the range of diseases that could be
targeted with JAK inhibitors will be discussed with emphasis on
hair disorders, including alopecia areata and androgenetic
alopecia.
Dr. Changelian is known for his key role in the discovery and
development of tofacitinib, a pan-JAK inhibitor, while working as a
scientist at Pfizer. In 1993, he first heard about the National
Institutes of Health’s discovery of an enzyme in the Janus family
of kinases involving the immune function. Seven years after
initiating the discovery program, Dr. Changelian and the Pfizer
immunology team selected tofacitinib for clinical development.
Tofacitinib became the first JAK inhibitor approved by the FDA for
an autoimmune disease. Dr. Changelian joined Aclaris in 2017 when
Aclaris acquired Confluence Life Sciences, Inc., a company founded
by former Pfizer scientists.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a dermatologist-led
biopharmaceutical company committed to identifying, developing, and
commercializing innovative therapies to address significant unmet
needs in dermatology, both aesthetic and medical, and immunology.
Aclaris’ focus on market segments with no FDA-approved medications
or where treatment gaps exist has resulted in the first
FDA-approved treatment for raised seborrheic keratoses and several
clinical programs to develop medications for the potential
treatment of common warts, alopecia areata, androgenetic alopecia,
and vitiligo. For additional information, please visit
www.aclaristx.com and follow Aclaris on LinkedIn.
Cautionary Note Regarding Forward-Looking
Statements
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements
as that term is defined in the Private Securities Litigation Reform
Act of 1995. These statements may be identified by words such as
"believe", "expect", "may", "plan," "potential," "will," and
similar expressions, and are based on Aclaris' current beliefs and
expectations. These forward-looking statements include expectations
regarding Aclaris’ clinical development of its JAK inhibitor drug
candidates. These statements involve risks and uncertainties that
could cause actual results to differ materially from those
reflected in such statements. Risks and uncertainties that may
cause actual results to differ materially include uncertainties
inherent in the conduct of clinical trials, Aclaris' reliance on
third parties over which it may not always have full control, and
other risks and uncertainties that are described in the Risk
Factors section of Aclaris' Annual Report on Form 10-K for the year
ended December 31, 2017 and other filings Aclaris makes with the
U.S. Securities and Exchange Commission from time to time. These
documents are available under the "Financial Information" section
of the Investors page of Aclaris' website at
http://www.aclaristx.com. Any forward-looking statements speak only
as of the date of this press release and are based on information
available to Aclaris as of the date of this release, and Aclaris
assumes no obligation to, and does not intend to, update any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Aclaris ContactMichael Tung, M.D.Senior Vice
President Corporate Strategy/Investor
Relations484-329-2140mtung@aclaristx.com
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aclaris Therapeutics (NASDAQ:ACRS)
Historical Stock Chart
From Jul 2023 to Jul 2024